CANINE CORONAVIRUS {#cesec1}
==================

 {#cesec2}

###  {#cesec3}

#### Definition {#cesec4}

I.Canine coronavirus (CCV) causes contagious enteritis of variable severity (rarely fatal) in young dogs.II.The true significance of this pathogen in juvenile diarrhea is not fully known, but it may contribute to the morbidity and mortality of other infectious enteropathies, such as canine parvovirus (CPV) ([@bib41]).

#### Cause and Pathophysiology {#cesec5}

I.CCV, a single-stranded (SS) ribonucleic acid (RNA) virus of the family Coronaviridae, is closely related to feline coronavirus and transmissible gastroenteritis virus of pigs.II.CCV is highly contagious via fecal--oral transmission.III.Fecal shedding results in environmental contamination, an important route of exposure.IV.CCV infects any age group, but clinical disease is usually seen only in very young puppies.V.After ingestion, the virus localizes in the villus tips of the small intestines, where it replicates and results in villous atrophy and crypt cell hyperplasia.

#### Clinical Signs {#cesec6}

I.AdultsA.Infected, seronegative adult dogs usually asymptomaticB.Possibly mild gastrointestinal (GI) signsII.PuppiesA.Acute onset of mild to severe, ± bloody diarrhea in neonatal and very young puppiesB.Lethargy, anorexia, vomiting ± dehydrationC.Typically self-limiting, but possibly life-threatening

#### Diagnosis {#cesec7}

I.Suspicious signalment, history, and clinical presentationII.Clinical pathology: findings nonspecific, leukopenia not recognizedIII.CCV-specific testingA.Virus identification is rarely necessary or indicated.B.Fourfold rise in immunoglobulin (Ig) G titer on paired serum samples is supportive, but rarely performed.C.Direct viral detection may be performed on feces.1.Electron microscopy (EM)2.Enzyme-linked immunosorbent assay (ELISA)3.Intestinal tissue fluorescent antibody (FA) testing (Tuchiya et al., 1993)D.Viral detection may also be done with intestinal tissue immunohistochemistry ([@bib10]).E.CCV can also be detected in the feces of clinically healthy dogs ([@bib44]).

#### Differential Diagnosis {#cesec8}

I.Canine parvovirusII.Parasites, bacterial enteritisIII.Canine distemper virus (CDV), canine herpesvirus (CHV)IV.Toxins, foreign bodies, intussusception, or metabolic diseases

#### Treatment {#cesec9}

I.Supportive care may be instituted, although many dogs require no therapy.II.See [Box 112-1](#cetextbox1){ref-type="boxed-text"} for treatment of GI signs.Box 112-1Therapy for Gastrointestinal Manifestations of Viral Disease\*\*Doses are recommended for both dogs and cats unless otherwise specified.1.Animals with vomiting ± moderate to severe diarrhea are kept NPO.2.Crystalloids (LRS, Plasmalyte, 0.9% NaCl) via parenteral routes (IV, intraosseous, SC) are indicated to rehydrate, replace ongoing losses, and maintain hydration.a.Maintenance: 55-66 mL/kg/day; rehydration and losses must be estimated and added to the maintenance fluid rate.b.SC fluids are not effective for moderate to severe dehydration.c.Potassium and dextrose supplementation are often required.3.Colloid therapy is indicated for moderate to severe hypoalbuminemia and hypotension.a.Hydroxyethyl starch (Hetastarch): give 10 mL/kg in dogs, 5 mL/kg in cats IV bolus or 20-30 mL/kg/day CRI.b.Plasma provides minimal oncotic support.4.Antiemetics may be useful if obstructive GI disease is ruled out, especially when risk of aspiration exists.a.Metoclopramide 0.2-0.4 mg/kg SC BID-TID or 1-2 mg/kg/day IV as CRI (dogs)b.Prochlorperazine 0.1-0.5 mg/kg IM, SC TID or chlorpromazine 0.2-0.4 mg/kg IM, SC TID (dogs)(1)Contraindicated in hypotensive or dehydrated animals(2)May cause sedation; contraindicated with seizure disordersc.Ondansetron 0.1-0.2 mg/kg SC, IV BID-QID for intractable vomiting5.Antibiotics BID-QID are given for hemorrhagic diarrhea, neutropenia, or suspected bacterial infection.a.Ampicillin 10-20 mg/kg IV TID-QID; gram-negative coverage may be inadequateb.Enrofloxacin 2.5-5.0 mg/kg SC BID for dogs; relatively contraindicated in growing puppies and kittens owing to potential cartilage damagec.Gentamicin 6-6.6 mg/kg IV, IM, or SC SID or amikacin 15-30 mg/kg IV, IM, or SC SID(1)Contraindicated in dehydration, hypotension, or renal failure(2)May cause renal failure, ototoxicity(3)Covers gram-negative bacteria onlyd.Cefazolin 22 mg/kg IV TID with enrofloxacin or gentocine.Cefoxitin 22 mg/kg IV TID6.H~2~-blocker therapy may decrease gastric acidity and its associated complications.a.Famotidine 0.5-1.0 mg/kg IV, SC, or IM SID-BIDb.Cimetidine 5-10 mg/kg IV, SC, or IM TIDc.Ranitidine 2 mg/kg IV BID7.Adjunctive therapy includes the following:a.Animals on NPO restrictions for 3 days or longer require parenteral nutrition.b.Whole blood, packed RBCs, or blood substitute are indicated for anemia.c.Routine nursing care is critical to keep IV sites clean and prevent urine or fecal scald.8.Recovery and realimentation are important.a.Small amounts of water are offered 12-24 hours after cessation of vomiting.b.If no vomiting occurs within 12-24 hours of water administration, small amounts of a bland diet are offered every 2-3 hours.c.Animals are gradually weaned onto maintenance requirements of a bland diet over 2-4 days.d.Bland diet is maintained for 1-3 weeks, followed by gradual reintroduction of a diet appropriate for age.*NPO*, Nothing by mouth; *LRS,* lactated Ringer solution; *CRI*, constant rate infusion; *GI*, gastrointestinal; *H~2~*, histamine~2~; *RBCs*, red blood cells.

#### Monitoring and Prevention {#cesec10}

I.The need for routine CCV vaccination is questionable, although inactivated and modified live virus (MLV) vaccines are available for at-risk populations.II.Avoid exposure of young puppies to potentially contaminated environments.III.CCV is inactivated by various disinfectants ([Table 112-1](#cetable1){ref-type="table"} ).TABLE 112-1Efficacy of Common Disinfectants against VirusesDISINFECTANT CLASSENVELOPED VIRUS[\*](#cetablefn1){ref-type="table-fn"}NONENVELOPED VIRUS[†](#cetablefn2){ref-type="table-fn"}Alcohols Ethyl alcohol++ Isopropyl alcohol+[‡](#cetablefn3){ref-type="table-fn"}−Aldehydes (gluteraldehyde)++Bisguanide (chlorhexidine)+[‡](#cetablefn3){ref-type="table-fn"}±Halogens Hypochlorite (bleach)++ Iodines (tinctures)+± Iodophores (providone-iodine)+±Peroxygens (hydrogen peroxide)++Phenolics *(Lysol)*+±Quartenary ammonium+−[^1][^2][^3][^4]Data from Greene CE: Environmental factors in infectious disease. p. 673. In Greene CE (ed): Infectious Diseases of the Dog and Cat. 2nd Ed. WB Saunders, Philadelphia, 1998; Love BC, Hirsch DC: Disinfectant and antiseptic use in small animal practice. p. 258. In Bonagura JD (ed): Kirk\'s Current Veterinary Therapy XIII: Small Animal Practice. WB Saunders, Philadelphia, 2000.IV.Viral shedding may occur for up to 6 months postinfection ([@bib41]).

CANINE DISTEMPER VIRUS {#cesec11}
======================

 {#cesec12}

###  {#cesec13}

#### Definition {#cesec14}

I.CDV is a highly contagious virus with either focal or multisystemic manifestations, and variable morbidity and mortality.II.Respiratory, GI, and neurological tissues are all targets.

#### Cause and Pathophysiology {#cesec15}

I.CDV is a SS-RNA virus of the family Paramyxoviridae and is closely related to measles virus of primates and rinderpest in domestic livestock.II.CDV is highly contagious.A.Large viral concentrations occur in respiratory secretions.B.It is commonly spread by aerosolization.C.Infective virus is also present in urine and other bodily fluids.D.Recovered dogs shed the virus for 60 to 90 days postinfection ([@bib13]).III.The virus is viable in cold and freezing environments, but susceptible to heat, drying, and ultraviolet light.IV.Younger animals are most susceptible to infection.V.Susceptibility is enhanced in older dogs not adequately vaccinated and with either concurrent stress or immunosuppressive conditions.VI.During systemic infection, CDV contacts upper respiratory epithelium; replicates within respiratory lymphatics; eventually disseminates to other lymphatic tissues, intestines, and liver; and produces viremia.A.Host immunity may be suppressed by the virus.B.Several outcomes are possible, depending on immunity and antibody (Ab) response.1.Adequate immunitya.Virus cleared with no illnessb.Central nervous system (CNS) invasion possible2.Partial immunitya.Virus spreads to epithelial tissues and CNSb.Mild or subclinical illnessc.Virus partially cleared, CNS persistence possible3.No immunitya.Viremia, epithelial and CNS infection, and viral persistenceb.Illness often severe and fatalVII.CNS infection is common, but the exact mechanism of entry into the CNS is unknown.A.Direct viral injury in animals with poor immunity results in acute multifocal encephalitis of gray and white matter.B.White matter lesions of demyelination are possible, and this noncytolytic form does not induce inflammatory changes.C.Chronic CNS infection leads to progressive dysfunction or relapse months to years after subclinical infection or apparent recovery (also called *old dog encephalitis*).

#### Clinical Signs {#cesec16}

I.Mild or subclinical infectionA.Mild lethargy, feverB.Cough, oculonasal discharge possibleC.Often unnoticedII.Systemic infectionA.Most common in young puppies, unvaccinated adults, and immunosuppressed animalsB.First clinical signs: fever and general malaiseC.Respiratory signs common1.Serous or mucopurulent oculonasal discharge soon after onset of fever2.Dry cough that becomes productive, and/or dyspneaD.GI signs common1.Anorexia, vomiting, dehydration, diarrhea2.Shock from hypovolemia or secondary bacterial sepsis and/or endotoxemiaIII.CNS infectionA.Signs often occur 1 to 3 weeks after recovery from systemic signs, but may be delayed for months to years after infection ([@bib13]).B.CNS manifestations may be the only signs of CDV infection.C.CNS signs vary from multifocal to localized, with variable progression.D.Neurological signs include seizures, vestibular disease, myoclonus, behavioral changes, hyperesthesia, tetraparesis, paraparesis, and cervical pain.1.Myoclonus (involuntary, repetitive muscle contraction of a specific area) is common, with or without other CNS signs.2.Classic focal facial seizures ("chewing gum seizures") may occur.IV.Additional manifestationsA.Dermatological: hard pad diseaseB.Ocular: keratoconjunctivitis sicca, chorioretinitisC.Dental enamel hypoplasia (pock marks)D.Transplacental infection possible

#### Diagnosis {#cesec17}

I.Compatible signalment, history, and clinical presentationII.General diagnostic testsA.Hematological evaluation: lymphopenia common with acute infectionsB.Rarely, pathognomonic cytoplasmic inclusions in blood cells or conjunctival scrapingsC.Hyperglobulinemia and hypoalbuminemia, or hypoglobulinemia with transplacental or neonatal infectionD.Cerebrospinal fluid (CSF) analysis1.Lymphocytic pleocytosis (\>5 to 10 cells/μL) and increased protein (\>25 mg/dL) common2.Inclusion bodies rare3.Possibly normal in noninflammatory demyelinating diseaseE.Radiography1.Thoracic radiographs normal, or possibly interstitial or alveolar patterns2.Intussusception ruled out with abdominal radiographs and/or ultrasonographyIII.CDV-specific testingA.Elevated serum Ab titers as detected by virus neutralization or ELISA support the diagnosis.1.Increased IgG titer indicates vaccination or either prior or recent CDV infection.2.A fourfold rise in IgG titers from paired serum samples suggests recent infection.3.Increased IgM titers without recent vaccination suggest acute infection.B.CSF Ab titers, if uncontaminated by blood, provide direct evidence of CNS infection.1.Vaccination does not produce detectable antibodies within the CSF.2.To rule out the possibility that serum Ab has contaminated CSF, a ratio of serum to CSF titers is compared for CDV and another vaccine component, such as canine adenovirus-2.C.FA testing performed on conjunctival or other epithelial scrapings, CSF, buffy coat, or bone marrow often yields false-negative results.D.Histopathologic evaluation may demonstrate inclusion bodies.

#### Differential Diagnosis {#cesec18}

I.Respiratory signs: infectious tracheobronchitis, aspiration, bacterial or parasitic pneumonia, rickettsial diseases, dysautonomiaII.GI signs: CPV or CCV, bacterial enteritis, toxin ingestion, foreign bodies, intussusception, metabolic diseaseIII.Neurological signs: hypoglycemia, toxins, hepatic encephalopathy, hypocalcemia, rabies, other causes of CNS disease (see Chapter 23).

#### Treatment {#cesec19}

I.Maintain adequate hydration.II.Administer antibiotics for secondary bacterial infections.III.Provide good nursing care with physical therapy (chest coupage) as needed.IV.Consider the use of bronchodilators.V.CNS therapy may involve the following:A.Phenobarbital 2.5 mg/kg PO, IM, or IV BID to TIDB.Diazepam 0.3 to 1.0 mg/kg IV to effect or 1 to 2 mg/kg per rectum during seizuresC.Diazepam, pentobarbital, or propofol IV for refractory or recurrent seizures (see Chapter 22)D.Myoclonus often refractory to medication and usually persists for lifeE.Prednisone 0.5 to 1.0 mg/kg/day PO for 2 weeks, with gradual tapering, for progressive CNS signs, refractory seizures, and late-onset encephalitis

#### Monitoring and Prevention {#cesec20}

I.Isolate sick dogs.II.Maternal Ab is usually gone by 12 weeks of age, but may interfere with initial vaccination ([@bib13]).III.MLV vaccines are administered 3 to 4 weeks apart, with at least one vaccine given after maternal Ab has waned.A.Annual to triennial vaccines are currently recommended to booster protection ([Table 112-2](#cetable2){ref-type="table"} ).TABLE 112-2Viral Vaccination Recommendations for Adult Dogs[\*](#cetablefn4){ref-type="table-fn"}VIRUSADMINISTRATION FREQUENCYCOMMENTS**Core vaccines**[†](#cetablefn5){ref-type="table-fn"}Canine distemper1 year, then every 3 years for MLV or recombinant productAnnual booster vaccines are suggested by some manufacturers; distemper-measles vaccine should never be used in adult dogsCanine adenovirus-21 year, then every 3 yearsParenteral MLV forms are generally preferred to killed or topicalMLV vaccinesCanine parvovirus1 year, then every 3 years for MLV vaccinesEfficacy may last \>3 yearsRabies1 year, then every 1 to 3 yearsLocal regulations impact frequency of booster vaccines**Noncore vaccines**[†](#cetablefn5){ref-type="table-fn"}Canine parainfluenza virus1 year, then every 3 yearsIntranasal or parenteral forms[^5][^6][^7]Adapted from Canine Vaccine Task Force: 2006 AAHA canine vaccine guidelines. J Am Anim Hosp Assoc 42:80, 2006.© 20082008Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.B.Measles vaccine provides cross-protection against CDV and may be given as an initial puppy vaccination at 6 to 12 weeks, when maternal Ab interferes with CDV vaccine response.C.Inactivated (i.e., killed virus) vaccine is used in pregnant or immunosuppressed animals, but it confers a lower degree and duration of immunity than MLV vaccines.D.MLV vaccines are contraindicated in pregnant or immunosuppressed animals.IV.Vaccination complications can occur.A.Encephalitis may develop in severely immunosuppressed puppies or in puppies whose dam received MLV vaccination while pregnant.B.CDV vaccine is inactivated by hyperthermia, and an attenuated response may occur with concurrent parvovirus infection or chemotherapy ([@bib13]).V.Recovery from natural infection provides prolonged immunity.VI.CDV is inactivated by various disinfectants (see [Table 112-1](#cetable1){ref-type="table"}).

CANINE HERPESVIRUS {#cesec21}
==================

 {#cesec22}

###  {#cesec23}

#### Definition and Cause {#cesec24}

I.CHV is a relatively common infection, but an uncommon cause of disease.II.When disease occurs, it causes abortions in pregnant bitches or a fatal hemorrhagic disease in puppies \<3 weeks of age.III.CHV, a double-stranded DNA virus of the family Herpesviridae, infects only Canidae.

#### Pathophysiology {#cesec25}

I.CHV requires close contact for transmission.II.It spreads transplacentally at birth or through direct dog-to-dog contact (e.g., during breeding).III.It is unstable in the environment, so it is rarely transmitted through fomites.

#### Clinical Signs {#cesec26}

I.Consequences of rare, transplacental infection include abortions, stillbirths, weak puppies, and puppies that succumb to neonatal infection.II.Neonatal infection occurs via exposure to the dam\'s vaginal secretions at birth or to infected littermates, and is most common during the first 3 weeks of life ([@bib2]).III.Signs in puppies 3 to 5 weeks old may be less severe and include neurological signs, such as trigeminal neuropathy, ataxia, and blindness.IV.Adults are usually asymptomatic.A.Females that appear healthy may experience infertility, abortion, or stillbirths.B.Genital lesions include papulovesicular lesions that regress and reappear in both males and females.C.CHV may play a minor role in canine respiratory infections.D.Latent infections recrudesce in some immunosuppressed dogs ([@bib35]).

#### Diagnosis {#cesec27}

I.Clinical pathologic evaluationA.Limited usefulness in neonates because of sampling difficulty and lack of specificityB.Puppies: thrombocytopenia, evidence of disseminated intravascular coagulopathy and increased liver enzyme activity (particularly alanine aminotransferase)II.CHV-specific testingA.Virus isolation from tissues of affected puppies is diagnostic.B.Serological testing indicates exposure, but does not diagnose active infection in adults.C.Multifocal hemorrhages and necrosis with inclusion bodies in epithelial tissues, or CHV identified in tissue via FA, EM, or polymerase chain reaction (PCR) assays are also conclusive.

#### Differential Diagnosis {#cesec28}

I.Neonatal deathA.Bacterial septicemia with *Salmonella* spp., *Streptococcus* spp.B.Other viral infections: CPV-1, CPV-2, CDVC.Protozoal diseasesII.Abortion and stillbirths: brucellosis, leptospirosis, bacterial metritis, CDV, protozoal diseases, endocrinopathies

#### Treatment {#cesec29}

I.Supportive therapy is typically unsuccessful.II.Provide parenteral fluids with oral or IV dextrose, nutritional support, nursing care, animal warming, and broad-spectrum antibiotics.III.Hyperimmune serum from recovered dogs may protect other puppies (\<5 weeks of age) in an affected litter; administer 1 to 2 mL intraperitoneally ([@bib2]; [@bib14]).IV.Rapid progression of neonatal disease makes the role of antiviral therapy questionable.V.Infected adult dogs remain latently infected because there is no way to clear all virus from the body.

#### Monitoring and Prevention {#cesec30}

I.Puppies that are kept warm (37° to 38° C \[99° to 100° F\]) have lower morbidity and mortality.II.Although bitches that have recovered from infection usually raise subsequent litters without problems, it is recommended they not be bred again.III.Isolate young puppies from dogs that might shed viral particles.IV.A preventative vaccine is available only in Europe.V.CHV is easily inactivated by most disinfectants (see [Table 112-1](#cetable1){ref-type="table"}).

CANINE PARVOVIRUS {#cesec31}
=================
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###  {#cesec33}

#### Definition {#cesec34}

I.CPV causes acute contagious enteritis with a high morbidity and mortality in immunologically naive dogs.II.Rarely, myocardial disease results from perinatal infection.

#### Cause {#cesec35}

I.Canine parvovirus-2II.SS-DNA virus of the family ParvoviridaeIII.CPV-2b: most common disease-causing strain in the United StatesIV.CPV-2: distinct from CPV-1 (including disease manifestations)

#### Pathophysiology {#cesec36}

I.Epidemiological findingsA.This highly contagious virus is shed primarily in the feces of infected and recovering animals.B.Fomites are a more common source of exposure than direct contact with feces, and CPV-2 persists in the environment.C.Incidence is higher in summer and late fall ([@bib21]).D.Immunologically naive animals (young puppies) are the most susceptible to CPV-2 infection; however, older, immunocompromised animals are also at risk.E.Reported breed predispositions include the rottweiler, American pit bull terrier, Doberman pinscher, and German shepherd dog ([@bib21]).II.PathogenesisA.After oronasal exposure (primary route) initial replication occurs in local lymphoid tissues, with subsequent viremia in 2 to 5 days.B.Rapidly dividing tissues (e.g., intestinal crypt cells, bone marrow leukocyte precursors) are preferentially infected; dissemination to the lungs, kidneys, and myocardium is possible.C.Infection of intestinal crypt cells and leukocyte precursors leads to classic manifestations of the disease.1.Crypt necrosis and villous blunting with secondary diarrhea2.Neutropenia with increased susceptibility to secondary bacterial infections and sepsisD.In utero or perinatal infections cause myocardial disease (rare) if insufficient maternal antibody is present.

#### Clinical Signs {#cesec37}

I.EnteritisA.Initially anorexia, depression, vomiting, ± fever ([@bib4])B.Diarrhea, often hemorrhagicC.Dehydration with inadequate fluid intake and losses via the GI tractD.Hypovolemic or endotoxic shock in severely affected dogs or progressive diseaseII.MyocarditisA.Entire litter affected (rare)B.Sudden death or congestive heart failure

#### Diagnosis {#cesec38}

I.General diagnostic testingA.Hematological findings1.Neutropenia is a classic finding.2.Lymphopenia, anemia, and thrombocytopenia are also possible.B.Serum biochemistry: panhypoproteinemia and electrolyte imbalances possibleC.Abdominal imaging1.Nonspecific findings suggestive of enteritis2.Used to rule out other intestinal diseases, especially intestinal intussusceptionII.CPV-2--specific testingA.Fecal ELISA for viral antigen is the most commonly used test, but false positives (MLV vaccine 5 to 12 days previously) and false negatives (limited fecal shedding) occur ([@bib32]).B.Fecal or intestinal EM, fecal PCR, and virus isolation are rarely used clinically.C.Serological testing is rarely performed, but a fourfold rise in convalescent IgG titers is diagnostic.D.Histological findings include intestinal crypt necrosis or nonsuppurative myocarditis (rare).

#### Differential Diagnosis {#cesec39}

I.GI signs: CCV, bacterial enteritis, parasites, CDV, CHV, toxins, foreign body, intussusception, metabolic diseasesII.Congestive heart failure: congenital heart disease, protozoal diseases, noncardiogenic pulmonary edema (e.g., electrocution, neurological disease, trauma)

#### Treatment {#cesec40}

I.Antiviral therapy is not necessarily required.A.Interferon omega 2.5 million units/kg IV SID for 3 consecutive days ([@bib7]) may be tried.B.Oseltamivir phosphate *(Tamiflu)* is a neuraminidase inhibitor used for influenza virus, and may be given for parvoviral enteritis at 2 mg/kg PO BID for 5 days (anecdotal).II.GI therapy is outlined in [Box 112-1](#cetextbox1){ref-type="boxed-text"}.A.Adjunctive therapy involves hyperimmune plasma transfusions (1.1 to 2.2 mL/kg IV) from recovered dogs (Cohn LA, unpublished data, 2006).B.Empirical deworming is used to eliminate concurrent intestinal parasites.C.Treatment with recombinant human granulocyte colony-stimulating factor (G-CSF) is not beneficial ([@bib42]).D.CPV-2 infection may be fatal, but many animals fully recover.III.Myocardial disease is extremely difficult to treat.A.Because the disease is rapidly progressive and fatal, therapeutic intervention is rarely attempted.B.Treat congestive heart failure in survivors.

#### Monitoring and Prevention {#cesec41}

I.Quarantine unvaccinated animals.II.Passive immunity is important in neonates.A.Maternal Ab titers \>1:80 (hemagglutination-inhibition) are protective ([@bib33]).B.Maternal Ab typically protects for 6 to 12 weeks and may interfere with vaccination responses up to 18 weeks of age ([@bib5]).III.Good acquired immunity is achieved through vaccination.A.High-titer potentiated MLV CPV-2 vaccines are preferred.1.They induce protective immunity in puppies when maternal Ab is present ([@bib27]).2.Annual ([@bib33]) to triennial booster vaccines (see [Table 112-2](#cetable2){ref-type="table"}) are recommended.B.Low-titer, MLV CPV-2 vaccines do not always protect puppies with high maternal Ab levels, even at 20 weeks of age, but the vaccines do provide adequate protection for older puppies and adults ([@bib20]).IV.Following natural infection, recovered animals have long-lasting immunity.V.The virus is resistant to most disinfectants (see [Table 112-1](#cetable1){ref-type="table"}).

RABIES VIRUS {#cesec42}
============
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###  {#cesec44}

#### Definition and Cause {#cesec45}

I.Rabies is an invariably fatal infection resulting in encephalitis in most mammals.II.Although now rare in domestic animals, the zoonotic potential of this fatal disease makes it crucial that every veterinarian understand the disease.III.Rabies virus (RV) is an SS-RNA virus if the family Rhabdoviridae.

#### Pathophysiology {#cesec46}

I.Epidemiological findingsA.RV is maintained in wildlife reservoirs worldwide (e.g., fox, skunk, bat, raccoon).B.Different wildlife reservoirs predominate in certain geographic areas and carry different RV variants.C.Cats have a higher incidence of RV infection than dogs in the United States.II.TransmissionA.It occurs primarily through contact with infectious particles in saliva via bite wounds or contamination of mucous membranes or open wounds.B.Other minor sources include other body fluids, particularly urine, airborne virus, or ingestion.C.Rabies in dogs and cats is usually contagious only if a bite exposure occurs.III.PathogenesisA.The virus replicates locally and then spreads along the peripheral nervous system axons to the CNS and back down the peripheral nervous system and cranial nerves to the salivary glands.B.Inoculation at the head often leads to signs of encephalitis more rapidly than inoculation elsewhere on the body.C.Viral shedding via saliva typically does not begin until 5 to 10 days before the onset of clinical signs.

#### Clinical Signs {#cesec47}

I.The onset of CNS signs is usually with in 2 to 24 weeks, but depends on the viral load inoculated, the degree of innervation at the site, the proximity of the site to the CNS, and the strain of RV.II.Classic clinical presentation is either "furious" or "paralytic," but not all cases fit these categories, and a combination of signs is possible.III.With the furious form of rabies, the disease course lasts only days.A.Behavioral changes, hyperexcitability, hyperesthesia, and aggression occur.B.Ataxia and seizures develop and are followed by death.IV.With the paralytic form, the disease course typically lasts about 1 week.A.Progressive ascending lower motor neuron paralysis begins at the inoculation site and leads to dysphagia, masticatory muscle paralysis, and laryngeal and pharyngeal dysfunction, with classic signs of salivation.B.Death is caused by respiratory paralysis.

#### Diagnosis {#cesec48}

I.History of a recent bite wound and classic clinical presentation may be helpful.II.Clinical pathologic findings are nonspecific.III.Antemortem testing may confirm RV infection, but can-not adequately rule it out.IV.Owing to the serious public health implications, euthanasia of animals suspected of RV infection is urgently recommended and often required by law.V.Postmortem testing confirms or denies the diagnosis.A.Submit the brain---chilled but not frozen---as soon as possible to a state diagnostic laboratory.B.Direct FA testing of the brain is the diagnostic method of choice.C.Additional tests on brain specimens include PCR for viral particles, histopathologic evaluation (intracellular inclusions or Negri bodies), and mouse inoculation ([@bib25]).D.RV strains may be identified to help determine the source of exposure.

#### Differential Diagnosis {#cesec49}

I.Dogs: CDV, acute polyradiculoneuritis, botulism, tick paralysis, pseudorabies, neoplasia, organophosphate intoxication, other intoxications, and other causes of meningitis and encephalitisII.Cats: toxoplasmosis, feline infectious peritonitis (FIP), feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), pseudorabies, thiamine deficiency, intoxications, and other causes of meningitis and encephalitis

#### Treatment {#cesec50}

I.Treatment is unsuccessful and RV infection is invariably fatal.II.Because of the public health risk, animals with suspected RV infection are euthanized.

#### Monitoring and Prevention {#cesec51}

I.Vaccination provides excellent protection against the disease.A.Vaccination in most states is initiated by a killed vaccine at 12 to 16 weeks of age, with a booster vaccination at 1 year of age followed by triennial boosters.B.Some states require yearly vaccination; some vaccines are approved for yearly use only (e.g., canary pox-vectored vaccines).C.The use of rabies vaccine has been associated with injection-site sarcomas in cats.II.In most municipalities, rabies vaccination for dogs and cats is required by law.III.Recommendations for preexposure vaccination and management and postexposure management are available yearly from the American Veterinary Medical Association (AVMA; [www.avma.org/issues/policy/rabies_control.asp](http://www.avma.org/issues/policy/rabies_control.asp){#interref1}) and from the Centers for Disease Control and Prevention (CDC; [www.cdc.gov/ncidod/dvrd/rabies](http://www.cdc.gov/ncidod/dvrd/rabies){#interref2}; see [Table 112-2](#cetable2){ref-type="table"}).IV.Use extreme care when handling an animal or its bodily fluids if RV infection is suspected.V.RV is susceptible to most disinfectants and does not survive well in the environment (see [Table 112-1](#cetable1){ref-type="table"}).

FELINE CORONAVIRUS {#cesec52}
==================
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###  {#cesec54}

#### Definition and Cause {#cesec55}

I.Feline coronavirus (FCoV) causes either subclinical infection or mild, transient diarrhea in exposed cats.II.Spontaneous mutation of enteric FCoV may lead to clinical FIP, which is associated with very high morbidity and mortality.III.FCoV is an SS-RNA virus of the family Coronaviridae.

#### Pathophysiology {#cesec56}

I.FCoV is highly contagious via fecal--oral transmission, but salivary, urinary, and transplacental sources of exposure are uncommon.II.Most infected cats shed the virus intermittently and then stop shedding, although some shed persistently.III.FCoV that has mutated to an FIP-causing form is seldom shed in feces, so epizootics are rare.IV.Although inactivated by most disinfectants, FCoV may persist in the environment (see [Table 112-1](#cetable1){ref-type="table"}).V.Enteric infection results in villous atrophy and mild, self-limiting diarrhea.VI.With FIP, a history of recent stress or illness may precede the disease.A.Mutated FCoV invades intestinal epithelium and enters macrophages, resulting in disseminated spread of mutated viral particles.B.Immunological response is ineffective and pathologic changes occur.C.Two forms of FIP are recognized.1.Effusive (wet) forma.Immune complexes circulate and are deposited in endothelia.b.A vasculitis ensues with exudation of protein-rich fluid into body cavities.c.The wet form is usually more rapidly progressive than the dry form.2.Noneffusive (dry) forma.An ineffective cell-mediated immune response is mounted against the virus.b.Pyogranulomatous inflammation in a variety of tissues results in disease.c.The dry form may become effusive in its terminal stages.

#### Clinical Signs {#cesec57}

I.Enteric FCoV: often subclinical or mild diarrheaII.FIPA.Young (\<2 years) and elderly cats more commonly affectedB.Sexually intact and purebred cats more commonly affectedC.Effusive FIP1.Common: fever, pale mucous membranes, dyspnea, abdominal distention2.Variable: abdominal masses, abdominal organomegaly, icterusD.Noneffusive FIP1.Development of clinical signs is often insidious.2.Signs reflect the body system affected.a.Hepatomegaly, icterus, abdominal masses, renomegalyb.Pathologic ocular findings: uveitis, chorioretinitisc.CNS signs, dyspnead.Fever and weight loss common

#### Diagnosis {#cesec58}

I.Enteric FCoV infectionA.Definitive diagnosis is seldom necessary.B.Antibody titers suggest prior exposure, but do not reflect fecal shedding or active infection.C.Viral particles identified in fecal specimens by PCR or EM have few, if any, implications for the health of an individual cat.II.FIP infectionA.General diagnostics tests1.Hematological findings: nonregenerative anemia, neutrophilia ± left shift2.Supportive biochemical findingsa.Hyperglobulinemia with a low albumin:globulin ratiob.Other potential findings: icterus, elevated liver enzymes, azotemia3.Serum electrophoresis: polyclonal gammopathy4.Fluid analysisa.Clear to straw-colored, viscous effusion with low to moderate cellularity, and high protein contentb.Contains lymphocytes, macrophages, and nondegenerate neutrophils5.Radiography: body cavity effusions ± organo-megaly, pulmonary infiltrates6.Ultrasonography: nodular lesions within organs, organomegaly, effusions (pleural, peritoneal, pericardial, retroperitoneal)B.Coronavirus-specific serological tests1.Detection of serum Ab identifies exposure to FCoV, but is not diagnostic of FIP.2.Titers cannot distinguish exposure to enteric FCoV from exposure to the mutated virus causing FIP.3.Titers cannot distinguish exposure to corona viruses of other species from exposure to FCoV.4.Most healthy cats with Abs to FCoV never develop FIP.5.Positive FCoV Ab titers do not suggest that the cat is shedding virus.6.Cats with FIP occasionally have negative titers, especially during terminal stages of disease.7.In cats with signs suggestive of FIP, high Ab titers support a diagnosis of FIP.C.PCR tests for coronavirus1.PCR may identify FCoV in cats with either FIP or enteric FCoV.2.It cannot distinguish between enteric FCoV and the FIP-causing mutated forms.3.The test result may be negative in a significant number of cats with confirmed FIP.4.Positive PCR results from body effusions support a diagnosis of FIP.5.A fecal PCR test identifies viral shedding; although persistent viral shedding does not increase the risk for development of FIP, it can be a source of exposure for other cats.D.Histopathologic findings1.Histopathologic evaluation remains the best method to diagnose FIP.2.Affected tissues exhibit pyogranulomatous inflammation with vasculitis and perivascular cuffing with mononuclear cells, macrophages, lymphocytes, and neutrophils.3.FA and immunohistochemical testing of tissue specimens from biopsy (ultrasound-guidance or surgically obtained hepatic or renal tissue) or necropsy may confirm FIP.

#### Differential Diagnosis {#cesec59}

I.Enteric FCoV infection with diarrhea: feline panleukopenia, parasites, dietary indiscretion, protozoal infections, bacterial infections, foreign body, and inflammatory bowel diseaseII.Effusive FIP: peritonitis, pyothorax, chylothorax, neo-plasia, heart failure, cholangiohepatitis, and disseminated fungal or bacterial infectionsIII.Noneffusive FIP: toxoplasmosis, fungal infection, neo-plasia, and cholangiohepatitis

#### Treatment {#cesec60}

I.Enteric FCoV with diarrheaA.Because the disease is usually subclinical or self-limiting, specific therapy is not often necessary.B.No known therapy reduces the small chance that FCoV-infected cats will develop FIP.II.Feline infectious peritonitisA.Treatment is unsuccessful because the disease is usually fatal.B.Spontaneous remissions occur rarely.C.Supportive care with nutritional supplementation, relief of effusions that impair respiration, blood transfusions, parenteral fluid therapy, and antibiotic therapy for secondary infections may help prolong life.D.Immunosuppressive or immunomodulatory therapy may benefit a small number of cats.1.Prednisone 2 to 4 mg/kg PO BID2.Cyclophosphamide 2.2 mg/kg PO 4 days/week or chlorambucil 20 mg/m^2^ PO every 2 to 3 weeks3.Human-recombinant interferon-α 30 U PO SID on alternating weeks4.Pentoxifylline: suggested therapy but data insufficientE.Clinical studies of other proposed treatments (e.g., vitamins E, A, C) are not availble.

#### Monitoring and Prevention {#cesec61}

I.Catteries and multicat householdsA.Control exposure to feces and disinfect fomites.B.Ab tests identify exposed cats but do not predict fecal shedding or propensity to develop FIP, so do not euthanize healthy cats based on positive Ab test results.C.Fecal PCR identifies chronic shedders; segregation may reduce exposures.D.Strategy to eradicate FCoV is as follows:1.Obtain negative (zero) titers on new cats.2.Segregate positive cats in the facility from negative cats.3.Keep all cats indoors.4.Remove kittens from seropositive queens at 5 to 6 weeks of age.II.VaccinationA.The available intranasal vaccine appears safe when used as directed.1.Temperature-sensitive vaccine virus replicates only in respiratory epithelium, inducing mucosal immunity.2.Vaccine efficacy is 50% to 75% for previously unexposed cats ([@bib37]).3.It is not indicated in low-risk cats, such as adults or cats in single-cat households.4.At-risk kittens possibly benefit from vaccination, with two doses given 3 to 4 weeks apart and followed by yearly booster vaccinations.5.Currently, the vaccine is not recommended for routine use ([Table 112-3](#cetable3){ref-type="table"} ).TABLE 112-3Viral Vaccination Recommendations for Adult Cats[\*](#cetablefn6){ref-type="table-fn"}VIRUSADMINISTRATION FREQUENCYCOMMENTS**Core vaccines**[†](#cetablefn7){ref-type="table-fn"}Panleukopenia1 year, then every 3 yearsEfficacy of MLV may last \>3 yearsMLV should not be administered to pregnant queensHerpesvirus-11 year, then every 3 yearsEither parenteral or topical MLV product may be givenInactivated-virus vaccine with an adjuvant is an alternativeCalicivirus1 year, then every 3 yearsEither parenteral or topical MLV product may be givenInactivated-virus vaccine with an adjuvant is an alternativeRabies1 year, then every 1 to 3 yearsLocal regulations impact frequency of booster vaccines**Noncore vaccines**[†](#cetablefn7){ref-type="table-fn"}Feline leukemia virusAnnuallyTest cats before vaccinationKittens and young cats are more susceptible to infection than adult catsConsider lifestyle risksFeline immunodeficiency virusAnnuallyTest cats before vaccinationVaccinated cats cannot be distinguished from infected catsConsider lifestyle risksFeline infectious peritonitisAnnuallyIt is not recommended for most cats[^8][^9][^10]Adapted from Richards JR, Elston TH, Ford RB et al: The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. J Am Vet Med Assoc 229:1405, 2006.© 20082008Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.B.Vaccination does not prevent mutation of FCoV in an infected cat.

FELINE IMMUNODEFICIENCY VIRUS {#cesec62}
=============================

 {#cesec63}

###  {#cesec64}

#### Definition and Cause {#cesec65}

I.FIV causes chronic infections with a long subclinical period, and eventual development of acquired immunodeficiency with associated clinical syndromes.II.FIV, a lentivirus, is a SS-RNA virus of the family Retroviridae that only infects Felidae and is closely related to human immunodeficiency virus.

#### Pathophysiology {#cesec66}

I.Epidemiological findingsA.Horizontal and vertical transmission occur, but verti-cal spread is not epidemiologically important.B.Close contact is required for transmission, and fomites are involved only minimally.C.Horizontal transmission occurs primarily via bite wounds, and also occurs via blood transfusions, contaminated needles and instruments, or other contact with bodily fluids.D.Males, particularly intact, outdoor cats that fight, are more commonly infected than females.E.Adults (middle aged and older) are infected more often than kittens.F.A higher seroprevalence of FIV occurs in areas with large outdoor cat populations.II.PathogenesisA.FIV initially replicates in lymphoid (including thymic) and salivary tissue, with subsequent dissemination to many tissues.B.As the cat mounts a partially effective immune response, the number of circulating viral particles lessens and the cat appears healthy.C.During the subclinical period (possibly many years), gradual deterioration in immune function occurs (not a true latency).D.Secondary infections and associated illness eventually occur, resulting in the terminal phase of disease.

#### Clinical Signs {#cesec67}

I.Acute infection may be inapparent, but can cause self-limiting fever, neutropenia, and lymphadenopathy.II.Lymphadenopathy is variably present during the subclinical period (months to years).III.Clinical illness has a variety of manifestations.A.Recurrent fevers, anorexia, malaise, gingivitis, stomatitis (common)B.Secondary infections of the GI, respiratory, and urinary tractsC.Inflammatory diseases of the eye ([@bib15])D.A variety of malignancies ([@bib23])E.Rare peripheral or central neurological dysfunction ([@bib39])F.Severe weight loss and cytopenia (terminally)

#### Diagnosis {#cesec68}

I.Hematological findingsA.Lymphopenia and neutropenia acutely, and during later stages of diseaseB.Anemia and thrombocytopeniaII.Serum biochemistry profile: hyperglobulinemia or findings related to secondary diseasesIII.Cytological evaluation of fine-needle aspirates of enlarged lymph nodes: hyperplasia or mimic lymphomaIV.FIV-specific diagnostic testingA.In-hospital ELISA tests identify Abs.1.FIV is not always detected during acute infection or during terminal stages.2.False positives can occur from maternal Ab, so retest positive kittens after 6 months of age ([@bib43]).3.False positives can occur in vaccinated cats.B.Although Western blot is used as a confirmatory test for a positive ELISA result, it cannot distinguish Ab formed in response to infection from maternal Ab or Ab formed in response to vaccination ([@bib29]).C.PCR assays are available but vary greatly in reliability ([@bib6]).

#### Differential Diagnosis {#cesec69}

I.Primary infections with any of the secondary pathogensII.FeLV infectionIII.Bone marrow infiltrative diseasesIV.NeoplasiaV.Chronic fungal infections

#### Treatment {#cesec70}

I.Asymptomatic catsA.Keep the animal indoors and well vaccinated for other diseases to minimize risks of other infections.B.No specific treatment is available.II.Symptomatic catsA.Provide supportive care and prompt therapy for secondary infections.B.Human recombinant G-CSF may be helpful for severe neutropenia (see Treatment under Feline Leukemia Virus).C.The use of recombinant human granulocyte-macrophage colony stimulating factor may lead to increased FIV load ([@bib3]).D.Other immune modulators and antiviral therapy may be tried (see Treatment under Feline Leukemia Virus).

#### Monitoring and Prevention {#cesec71}

I.A vaccine is available but does not confer perfect protection ([@bib22]).A.Test cats for FIV before administering the vaccine.B.The vaccine is effective for at least 12 months.C.Vaccinated cats can test positive on ELISA and Western blot FIV Ab tests.D.Consider microchip identification for all vaccinated cats so that ownership and FIV vaccination status can be determined.E.Vaccine is not currently recommended for routine use (see [Table 112-3](#cetable3){ref-type="table"}).II.Discourage fighting, and do not breed infected cats.III.Ideally, separate FIV-positive cats from FIV-negative housemates; however, unless they fight, the risk of transmission with normal contact (e.g., sharing litter boxes, food bowls) is low.

FELINE LEUKEMIA VIRUS {#cesec72}
=====================
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###  {#cesec74}

#### Definition and Cause {#cesec75}

I.FeLV causes a chronic infection that may induce neoplasia, immune deficiency, or bone marrow suppression.II.FeLV is an SS-RNA virus of the family Retroviridae, subfamily Oncornavirinae.

#### Pathophysiology {#cesec76}

I.Epidemiological findingsA.Horizontal and vertical transmission occur.B.Close contact is required, and fomites are minimally involved.C.FeLV, though shed in all bodily secretions, is trans-mitted primarily via saliva (usually during grooming); bite wounds; and shared use of food bowls, water bowls, and litter boxes.D.Rarely, transmission occurs transplacentally via the milk during nursing and through blood transfusions, needles, or surgical instruments.E.Viral particles are shed from both ill and healthy infected cats.F.Kittens are far more susceptible to infection than adult cats.II.PathogenesisA.Many outcomes are possible after exposure, including recovery, latent infection, or persistent viremia.B.The outcome depends on the subgroup of FeLV, age of the cat, immune response, and other variables.C.If the initial immune response is ineffective, viremia occurs with replication in lymphoid tissue and bone marrow.D.With an effective immune response, viremia ceases, but virus may remain integrated in bone marrow cells.1.Latently infected cats are not viremic and not a source of exposure for other cats.2.Infections can remain latent for life or may reactivate during stress or immunosuppression.E.Many viremic cats remain persistently viremic, with viral particles in bone marrow, epithelial tissues, and salivary glands.1.Persistently viremic cats may be healthy for a period of time or develop one of several clinical diseases.2.Malignancy is thought to result from insertional mutagenesis during viral replication.3.Antibodies to feline oncornavirus cell-associated membrane antigen protect the cat from malignancy, but not from other disease manifestations.4.Direct viral invasion of stem cell precursors or stromal damage causes myelosuppression.5.Immunosuppression may arise from lymphopenia and alterations in lymphocyte function.6.Decreased T suppressor cells and antigen--Ab complexes contribute to immune-mediated disease.

#### Clinical Signs {#cesec77}

I.Acute infection has a variety of manifestations.A.Often subclinicalB.Fever, depression, diarrhea, lymphadenopathy, ± leukopeniaC.Possible apparent recovery with no signs for months to yearsII.Cats with latent infection may be asymptomatic.III.Immunosuppression with secondary infections is the major cause of morbidity and mortality.IV.Myelosuppression causes nonregenerative anemia, leukopenia, and thrombocytopenia.V.Malignancy has several forms.A.Lymphoma is the most common neoplasia associated with FeLV infection.B.Clinical signs of lymphoma reflect the site involved, and include dyspnea (mediastinal); uremia (renal); and ataxia, paralysis, or seizures (CNS).C.Less commonly, hematopoietic malignancies (leukemias) develop and can involve any cell line, with clinical signs reflecting a reduction in normal hematopoietic cell numbers.VI.Other signs include evidence of immune-mediated hemolytic anemia (IMHA), glomerulonephritis, infertility, abortion, and osteochondromatosis.

#### Diagnosis {#cesec78}

I.Hematological findingsA.Nonregenerative anemia, macrocytic anemia, nucleated red blood cellsB.Possibly circulating blast cells, cytopenia, or leukemiaII.Serum biochemistries and urinalysis: nonspecific changes reflecting secondary conditionsIII.Lymph node, bone marrow, or mass aspirates: confirm neoplasia or secondary infectionIV.Radiography and ultrasonography: useful to identify neoplasiaV.FeLV-specific diagnostic testingA.A very sensitive and specific ELISA test detects circulating FeLV p27 core antigen.1.No false positives occur with maternal Abs.2.In-hospital kits can be used on serum, plasma, whole blood, saliva, or tears; saliva and tears are less reliable than serum.3.ELISA tests are positive earlier in infection than FA tests.4.Test results may revert from positive to negative with latent or cleared infection, so confirm a positive ELISA result by FA testing or a second ELISA test in 1 to 3 months.B.FA tests are confirmatory.1.FA detects p27 core antigen in leukocytes and platelets from blood or bone marrow.2.Because a positive FA test means the virus has repli-cated in precursor cells in the bone marrow, positive cats are unlikely to revert to a negative status.C.Culture or FA of bone marrow samples can be done to diagnose latent FeLV infection.D.PCR has no advantage over ELISA on blood samples and is useful only to identify FeLV in preserved neoplastic tissues.E.Identification of FeLV does not confirm a particular illness is secondary to FeLV.

#### Differential Diagnosis {#cesec79}

I.Acute illness: feline panleukopenia, FCoV, bacterial infections, FIPII.Anemia: hemorrhage, hemotrophic *Mycoplasma* spp. (see Chapter 115), chronic disease, renal failure, IMHA, histoplasmosis, atypical tuberculosis, myelophthisis, toxin exposure, etc.III.Neoplasia: non--viral-related leukemia and lymphoma, non-neoplastic causes of lymphadenopathy, pleural effusion, renomegaly, etc.

#### Treatment {#cesec80}

I.No specific treatment is necessary in asymptomatic cats.II.FeLV-induced neoplasia is treated similarly to non-FeLV neoplasia.III.Myelosuppression is addressed as follows:A.Anemia1.Blood transfusion may be life saving.2.Although erythropoietin levels in anemic FeLV-positive cats are elevated, short-term use of exogenous erythropoietin is potentially beneficial at 100 U/kg SC 3 times per week ([@bib3]).3.Address other causes of anemia, such as hemo-trophic *Mycoplasma* spp. infection and IMHA.B.Neutropenia1.The use of human recombinant G-CSF (5 μg/kg/day SC for ≤2 weeks) in severe neutropenia is controversial ([@bib34]; [@bib16]; [@bib3]), because at higher doses or for longer periods it may cause production of anti-bodies to feline colony stimulating factors.2.Consider prophylactic antibiotics.IV.Secondary bacterial infections require prompt therapy with appropriate antibiotics.V.Immune modulator and antiviral therapy may be tried, but evidence of efficacy is slim ([@bib31]).A.*Staphylococcus aureus* protein A 10 μg/kg IP twice weeklyB.Human recombinant interferon-α 30 U PO SID on alternating weeksC.Feline recombinant interferon omega 1 × 10^6^ U/kg/day SC for 5 consecutive days in 3 series, beginning on days 0, 14, and 60 ([@bib8]).

#### Monitoring and Prevention {#cesec81}

I.Isolate cats with FeLV from noninfected cats; keep infected cats indoors, vaccinate them for other infectious diseases, and do not breed them.II.Vaccination involves the following (see [Table 112-3](#cetable3){ref-type="table"}).A.Test before FeLV vaccination, because vaccination of positive cats provides no benefits.B.Vaccination is not indicated for low-risk cats (e.g., indoor cats, single-cat households, or households in which all cats test negative).C.Killed and subunit vaccines are equally efficacious.D.Vaccine efficacy is \<100%, and estimates of true effi-cacy vary ([@bib28]; [@bib24]).E.Initially give two vaccines 3 to 4 weeks apart, with annual booster vaccinations.F.Use of FeLV vaccine has been associated with injection-site sarcomas in cats.

FELINE PARVOVIRUS {#cesec82}
=================
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###  {#cesec84}

#### Definition and Cause {#cesec85}

I.Feline panleukopenia is a highly contagious, acute enteric disease of young cats, typically accompanied by severe leukopenia and high morbidity and mortality.II.In utero or early neonatal infection may cause cerebellar disease.III.Feline parvovirus (FPV), an SS-DNA virus of the family Parvoviridae, is related to CPV-2, which is rarely isolated from cats with panleukopenia.

#### Pathophysiology {#cesec86}

I.EpidemiologyA.FPV is highly contagious to all domestic and wild members of the family Felidae.B.Virus is shed in all body secretions, with fecal shedding being the primary source of infection.C.Transmission is from contact with infected animals, contaminated environment, or fomites.D.FPV is seldom encountered in vaccinated domestic cats, but is problematic in feral, shelter, and stray cats.E.Disease is most common in 3- to 5-month-old kittens, because most cats \>1 year old are immune from subclinical infection and younger kittens are protected by maternal Abs.II.PathogenesisA.After oronasal exposure, the virus replicates in regional lymph nodes and causes viremia.B.FPV preferentially infects rapidly dividing cells (e.g., intestinal epithelial cells, lymph tissue, hematopoietic cells of bone marrow).C.Secondary GI bacterial infection, translocation of gut bacteria, and increased susceptibility to bacterial infection and sepsis all contribute to the clinical signs produced.

#### Clinical Signs {#cesec87}

I.Adult cats: usually asymptomaticII.KittensA.Initial signs: fever, lethargy, complete anorexia, vomiting, diarrhea (sometimes hemorrhagic), severe dehydrationB.Outcome: peracute death or spontaneous recovery, with milder disease in older kittensIII.Transplacental and early neonatal infectionA.Early gestational infection: fetal resorption, infertility in apparently healthy queensB.Late gestational or neonatal infection1.Abortion of mummified fetuses, stillbirths2.CNS abnormalities: cerebellar hypoplasia with hypermetria and intention tremorsC.Other signs of in utero infection: hydrocephalus, hydranencephaly, retinal dysplasia

#### Diagnosis {#cesec88}

I.Hematological findingsA.Severe leukopenia, neutropenia, variable lymphopenia (early)B.Rebound leukocytosis (often pronounced) during the recovery phaseC.Anemia: rarely severe with intestinal blood lossD.ThrombocytopeniaII.Serum biochemistry profileA.Increased hepatic enzyme activityB.Azotemia, electrolyte imbalancesIII.Specific diagnostic testingA.Canine parvoviral fecal ELISA kits can detect FPV antigen (imperfect sensitivity).B.Virus isolation (fecal material and/or urine) is not routinely used.C.A fourfold increase in paired serum Ab titers is diagnostic, but the test is not commercially available.IV.Histopathologic findings are similar to those with CPV.

#### Differential Diagnosis {#cesec89}

I.Bacterial enteric infectionII.SepticemiaIII.ParasitismIV.FeLV, FCoVV.GI obstruction

#### Treatment {#cesec90}

I.Provide supportive care as for CPV (see [Box 112-1](#cetextbox1){ref-type="boxed-text"}).II.CNS signs are not treatable but are nonprogressive, and many affected kittens can be functional pets.

#### Monitoring and Prevention {#cesec91}

I.Passive immunityA.Colostral Ab prevents infection and interferes with vaccination up to 12 weeks of age.B.Plasma provides passive immunity (up to 4 weeks) if the kitten is colostrum-deprived.II.Active immunityA.Inactive (killed virus) vaccine1.Requires at least two administrations to be effective2.Safe in pregnant queens or young kittens (\<4 weeks of age)B.MLV vaccines1.They provide long-lasting immunity, although yearly booster vaccinations are still recommended by manufacturers.2.They are not safe in pregnant queens and poten-tially cause neurological dysfunction in kittens.3.Give kittens at least two vaccines, with at least 1 dose occurring after 12 weeks of age.4.For current recommendations, see [Table 112-3](#cetable3){ref-type="table"}.III.Natural infection produces lifelong immunity.IV.FPV is resistant to environmental degradation and to many disinfectants (see [Table 112-1](#cetable1){ref-type="table"}).

MISCELLANEOUS VIRAL INFECTIONS {#cesec92}
==============================

See [Table 112-4](#cetable4){ref-type="table"} .TABLE 112-4Other Viruses Affecting Dogs and CatsVIRUSSPECIESPATHOPHYSIOLOGYCLINICAL SIGNSDIAGNOSISTREATMENT/PREVENTIONFeline sarcoma virusCatRequires FeLV to replicateInduces multicentric fibrosarcoma in young catsUnrelated to injection-site sarcomasSolitary or multiple cutaneous masses ± visceral metastasesFeLV positive with fibrosarcomaWide surgical excisionFeline syncytium-forming virusCatHighly prevalent, but rarely produces diseaseCoinfection with FeLV results in immune complex deposition in jointsMost infections are asymptomaticSevere progressive polyarthritis may occurInflammatory joint tap, FA serologyDiseased cats are FeLV positiveTreatment unrewardingImmunosuppressive therapy with prednisone or cyclophosphamide may provide some reliefAstrovirusCatUnknown clinical significanceExperimentally, fecal--oral transmission occursDiarrhea, anorexia ± vomiting,EM of fecesSupportive careRoutine disinfectionNo vaccine is availablePoxvirusCatFound in Europe and AsiaOronasal or skin inoculationSpreads via blood stream to distant skinSingle or multiple skin lesions with scabs ± draining cellulitisVirus culture, EM of scab, FA test for serum AbSupportive careVaccine not availableZoonotic potentialBorna disease virusCatFound in EuropeBelieved to cause acute progressive nonsuppurative gray matter encephalomyelitisFever and anorexia followed by behavioral change, stifflegs, ataxia, ± seizures, salivation, constipation, altered visionHistopathology, IHCSupportive careVaccine not availablePapillomavirusDog, catSpecies-specific virus infects basal cellsYoung and/or immunodeficient animals affectedSingle or multiple oral, ocular, or cutaneous proliferative "wart-like" lesionsLesions often more plague-like in catsVisual diagnosis ± histopathology and virus identificationSpontaneous regression typicalMay be excised if interfere with functionPseudorabies virusDog, catPigs are common reservoir, with virus ingested in raw porkVirus travels through nerves to brain, often to brainstemPeracute illnessBehavioral changes, GI signs, dyspnea, intense pruritusCranial nerve deficits are commonDirect FA, PCR, VI, rabbit inoculationTypically fatal despite supportive carePrevent exposure to pigs, raw porkNo commercial vaccine availableRotavirusDog, catInfects epithelial cells of intestinal villi in dogs and catsClinically affected dogs are usually young puppiesHigh rate of infection but rare disease in catsNo signs or mild diarrhea for several daysSevere, fatal diarrhea can occur in young puppiesELISA, EM of feces, FA of tissueSupportive careVaccine not availableCanine adenovirus-1 (CAV-1; infectious canine hepatitis)DogHighly contagious, shed in secretionsYoung, unvaccinated dogs most commonly affectedViremia leads to hepatocyte and endothelial damage causing hepatic necrosis, disseminated intravascular coagulation, ± neurological signsSigns may be peracute, acute, or mild/subclinicalFever, abdominal pain, vomiting, diarrhea, icterus, lymphadenopathy may occurMilder signs with possible corneal edema and anterior uveitis may be notedPaired Ab titers, virus culture, histopathology (inclusion bodies), FA testing of tissuesPassive (up to 7 wk of age) or acquired immunity is protectiveModified live canine adenovirus-2 vaccine provides protectionCAV-1 vaccines are avoided owing to risk of secondary corneal edemaCanine parvovirus-1DogAffects puppies \<3 wk; may cross placentaInfects lymphoid tissue and rapidly dividing cellsSudden death or GI signs, dyspnea, crying ("fading puppy syndrome")± AbortionsEM of feces, hemagglutination inhibitionSupportive care typically unrewardingVaccine not availableCanine influenza virusDogHighly contagious respiratory virus of high morbidity but low mortalityHemorrhagic pneumonia is rare but life-threatening.Secondary bacterial infections account for most mortalityCough (often soft), fever, and nasal discharge are commonPaired antibody titers, PCR assay, viral isolationNo vaccine yet availableTreatment is largely supportive and includes antibiotics for secondary bacterial infections[^11][^12]

Doses are recommended for both dogs and cats unless otherwise specified.

[^1]: +, Susceptible; ±, somewhat susceptible; --, not susceptible.

[^2]: Enveloped viruses include canine distemper, coronaviruses, herpesviruses, rabies virus, and feline leukemia and immunodeficiency viruses.

[^3]: Nonenveloped viruses include canine adenoviruses, parvoviruses, and feline calicivirus.

[^4]: Rabies virus is not susceptible.

[^5]: *MLV,* Modified live virus.

[^6]: Vaccination protocols must be tailored to the individual dog in a given environment. This table provides guidelines only and does not address vaccine recommendations for nonviral diseases (bordetellosis, leptospirosis, borreliosis).

[^7]: Core vaccines are recommended for all dogs; noncore vaccines are optional and recommended only in some dogs.

[^8]: *MLV,* Modified live virus.

[^9]: Vaccination protocols must be tailored to the individual cat in a given environment. This table provides guidelines and does not address vaccine recommendations for nonviral diseases (chlamydophilosis, bordetellosis).

[^10]: Core vaccines are recommended for all cats; noncore vaccines are optional and recommended only in some cats.

[^11]: *FeLV*, Feline leukemia virus; *FA*, fluorescent antibody; *EM*, electron microscopy; *Ab*, antibody; *IHC*, immunohistochemistry; *GI,* gastrointestinal; *PCR*, polymerase chain reaction; *VI*, virus isolation.

[^12]: *ELISA*, Enzyme-linked immunosorbent assay.
